{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:36:15Z","timestamp":1793504175423,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Plasma Epstein-Barr virus (EBV) DNA is considered a biomarker for nasopharyngeal carcinoma (NPC). However, its long-term role in NPC development is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 1363 participants seropositive for EBV VCA-IgA and EBNA1-IgA in a community-based NPC screening program in southern China were tested for plasma EBV DNA levels by real-time qPCR between 2008 and 2015. New NPC cases were confirmed by active follow-up approach and linkage to local cancer registry through the end of 2016. Cox proportional hazards regression analysis was performed to calculate the hazard ratios (HRs) for NPC risk with plasma EBV DNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were newly diagnosed during a median 7.5\u2009years follow-up. NPC incidence increased with the plasma EBV DNA load ranging from 281.46 to 10,074.47 per 100,000 person-years in participants with undetectable and\u2009\u2265\u20091000 copies\/ml levels; the corresponding cumulative incidence rates were 1.73 and 50%. Furthermore, plasma EBV DNA loads conferred an independent risk for NPC development after adjustment for other risk factors, with HRs of 7.63 for &gt;\u20093\u2013999 copies\/ml and 39.79 for \u22651000 copies\/ml. However, the HRs decreased gradually after excluding NPC cases detected in the first 2 to 3\u2009years and became statistically nonsignificant by excluding cases detected during the first 4\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated plasma EBV DNA can predict NPC risk over 3\u2009years. Monitoring plasma EBV DNA can be used as a complementary approach to EBV serological antibody-based screening for NPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08408-0","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T11:20:28Z","timestamp":1622546428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population"],"prefix":"10.1186","volume":"21","author":[{"given":"Wen-Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Hang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"6","key":"8408_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"8408_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757\u201368. https:\/\/doi.org\/10.1038\/nrc1452.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"8408_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1535-6108(04)00119-9","volume":"5","author":"KW Lo","year":"2004","unstructured":"Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5(5):423\u20138. https:\/\/doi.org\/10.1016\/S1535-6108(04)00119-9.","journal-title":"Cancer Cell"},{"issue":"23","key":"8408_CR4","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1128\/JVI.78.23.13028-13036.2004","volume":"78","author":"Y Chang","year":"2004","unstructured":"Chang Y, Lee HH, Chang SS, Hsu TY, Wang PW, Chang YS, et al. Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol. 2004;78(23):13028\u201336. https:\/\/doi.org\/10.1128\/JVI.78.23.13028-13036.2004.","journal-title":"J Virol"},{"issue":"11","key":"8408_CR5","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1128\/JVI.00013-12","volume":"86","author":"N Sivachandran","year":"2012","unstructured":"Sivachandran N, Wang X, Frappier L. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol. 2012;86(11):6146\u201358. https:\/\/doi.org\/10.1128\/JVI.00013-12.","journal-title":"J Virol"},{"issue":"12","key":"8408_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16(12):789\u2013802. https:\/\/doi.org\/10.1038\/nrc.2016.92.","journal-title":"Nat Rev Cancer"},{"key":"8408_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-319-22834-1_8","volume":"391","author":"J McKenzie","year":"2015","unstructured":"McKenzie J, El-Guindy A. Epstein-Barr virus lytic cycle reactivation. Curr Top Microbiol Immunol. 2015;391:237\u201361. https:\/\/doi.org\/10.1007\/978-3-319-22834-1_8.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"8408_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019100","volume":"6","author":"SM Cao","year":"2011","unstructured":"Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, et al. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One. 2011;6(4):e19100. https:\/\/doi.org\/10.1371\/journal.pone.0019100.","journal-title":"PLoS One"},{"issue":"26","key":"8408_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa011610","volume":"345","author":"YC Chien","year":"2001","unstructured":"Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345(26):1877\u201382. https:\/\/doi.org\/10.1056\/NEJMoa011610.","journal-title":"N Engl J Med"},{"issue":"3","key":"8408_CR10","first-page":"263","volume":"20","author":"XM Zhang","year":"2006","unstructured":"Zhang XM, Zhong JM, Tang MZ, Zhang XG, Liao J, Zheng YM, et al. Comparison of IgA\/VCA, IgA\/EA, IgG\/EA in immunoenzyme methods and ZEBRA ELISA in early diagnosis of nasopharyngeal carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006;20(3):263\u20135.","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"issue":"2","key":"8408_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ijc.26380","volume":"131","author":"Y Liu","year":"2012","unstructured":"Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012;131(2):406\u201316. https:\/\/doi.org\/10.1002\/ijc.26380.","journal-title":"Int J Cancer"},{"issue":"5","key":"8408_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cncr.27853","volume":"119","author":"WY Wang","year":"2013","unstructured":"Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963\u201370. https:\/\/doi.org\/10.1002\/cncr.27853.","journal-title":"Cancer"},{"key":"8408_CR13","doi-asserted-by":"publisher","unstructured":"Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, Sun B, Hsu MM, Chen IH, Chen JY, Yang CS, Mittl BL, Chou SP, Ruggles DD, Goldstein AM, Hildesheim A: Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004, 111(1):117\u2013123, 1, DOI: https:\/\/doi.org\/10.1002\/ijc.20222.","DOI":"10.1002\/ijc.20222"},{"key":"8408_CR14","doi-asserted-by":"publisher","unstructured":"Chen GH, Liu Z, Ji MF, Pfeiffer RM, Huang QH, Lu YQ, et al. Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening. Int J Cancer. 2021;148(10):2398-406. https:\/\/doi.org\/10.1002\/ijc.33424.","DOI":"10.1002\/ijc.33424"},{"issue":"3","key":"8408_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kws404","volume":"177","author":"Z Liu","year":"2013","unstructured":"Liu Z, Ji MF, Huang QH, Fang F, Liu Q, Jia WH, et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in southern China. Am J Epidemiol. 2013;177(3):242\u201350. https:\/\/doi.org\/10.1093\/aje\/kws404.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"8408_CR16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","volume":"30","author":"MF Ji","year":"2019","unstructured":"Ji MF, Sheng W, Cheng WM, Ng MH, Wu BH, Yu X, et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019;30(10):1630\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdz231.","journal-title":"Ann Oncol"},{"issue":"5","key":"8408_CR17","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cam4.2083","volume":"8","author":"T Hu","year":"2019","unstructured":"Hu T, Lin CY, Xie SH, Chen GH, Lu YQ, Ling W, et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr virus: an analysis of a prospective study in southern China. Cancer Med. 2019;8(5):2561\u201371. https:\/\/doi.org\/10.1002\/cam4.2083.","journal-title":"Cancer Med"},{"issue":"6","key":"8408_CR18","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.20099","volume":"100","author":"JY Shao","year":"2004","unstructured":"Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin a\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100(6):1162\u201370. https:\/\/doi.org\/10.1002\/cncr.20099.","journal-title":"Cancer"},{"issue":"8","key":"8408_CR19","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1002\/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO;2-H","volume":"71","author":"K Shanmugaratnam","year":"1993","unstructured":"Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer. 1993;71(8):2689\u201397. https:\/\/doi.org\/10.1002\/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO;2-H.","journal-title":"Cancer"},{"issue":"6","key":"8408_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdz106","volume":"30","author":"AD King","year":"2019","unstructured":"King AD, Woo JKS, Ai QY, Chan JSM, Lam WKJ, Tse IOL, et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann Oncol. 2019;30(6):977\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdz106.","journal-title":"Ann Oncol"},{"issue":"1","key":"8408_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12935-021-01862-7","volume":"21","author":"W Liu","year":"2021","unstructured":"Liu W, Chen G, Gong X, Wang Y, Zheng Y, Liao X, et al. The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis. Cancer Cell Int. 2021;21(1):164. https:\/\/doi.org\/10.1186\/s12935-021-01862-7.","journal-title":"Cancer Cell Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08408-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T11:23:27Z","timestamp":1622546607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08408-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8408"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08408-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"19 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A written informed consent was obtained from each participant and this study was approved by the Ethics Review Committee of the Sun Yat-sen University Cancer Center (NCT00941538, Clinical Trials.gov).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors are approved of this submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"651"}}